AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

AC Immune S.A.NASDAQ: ACIU

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization remains negative

Q1 FY2026 depreciation & amortization was CHF 0, compared with CHF 612K a year earlier. Trailing-twelve-month depreciation & amortization was CHF 1.61M. Over 3 fiscal years it compounded at +2.0% a year.

Context

  • Depreciation & amortization amounted to 70.1% of revenue in FY2025, up 62.1 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near CHF 0 or moves back toward the trailing-twelve-month quarterly average of CHF 403.26K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 0-100.0% QoQ
Last fiscal yearDec 2025
CHF 2.5M+15.8% YoY
LTMMar 2026
CHF 1.61M-27.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+15.8%——
3-year CAGR+2.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

CHF · from the income statement

Latest · FY2025
2.5M CHF
Year-over-year change
+15.8%
4-year CAGR
+1.0%

Depreciation & Amortization vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -27.3% is the 9th highest of 10, against a peer median of +5.0%.
  • Depreciation & amortization amounts to 43.6% of revenue for ACIU, versus a peer median of 62.7%.
ACIU Competitors
Depreciation & Amortization for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$19.68M USD-2.6%+2.9%28.9%
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M USD-42.2%-13.8%33645.2%
ANNXAnnexon, Inc.LTM Mar 2026$3.06M USD+36.2%+7.2%—
AMRNAmarin Corporation plcLTM Mar 2026$2.93M USD-1.6%-0.7%1.4%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$1.77M USD+61.3%+8.0%—
ACIUAC Immune S.A.LTM Mar 2026CHF 1.61M CHF-27.3%+2.0%43.6%
MREOMereo BioPharma Group plcLTM Mar 2026$1.25M USD+15.6%+8.7%249.7%
ANROAlto Neuroscience, Inc.LTM Mar 2026$605K USD+5.0%+24.6%—
SLNSilence Therapeutics plcLTM Mar 2026$577.79K USD—+4.5%62.7%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$328K USD+19.3%-0.6%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$257.68K USD+3.1%-0.9%—
Peer median (excluding ACIU) —+5.0%+3.7%62.7%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.94M14.8M27.31M3.57M
Cost of Revenue0054.61M62.57M0
Gross Profit03.94M(39.81M)(35.26M)3.57M
Gross Margin—100.0%-268.9%-129.1%100.0%
Research & Development62.28M60.34M54.61M62.57M56.44M
Selling, General & Admin10.88M9.58M10.58M11.43M11.65M
Operating Expenses79.01M74.78M13.82M17.12M72.44M
Depreciation & Amortization2.41M2.36M2.22M2.16M2.5M
EBITDA(70.01M)(68.03M)(51.83M)(48.62M)(67.75M)
EBITDA Margin—-1728.7%-350.2%-178.0%-1896.2%
Operating Income(79.01M)(70.85M)(53.62M)(52.38M)(68.86M)
Operating Margin—-1800.4%-362.3%-191.8%-1927.3%
Interest Income6.49M69K1.04M3.2M1.87M
Interest Expense581K355K176K133K191K
Other Income / Expenses6.02M107K(599K)1.47M(1.58M)
Income Before Tax(72.99M)(70.74M)(54.22M)(50.91M)(70.45M)
Pre-Tax Margin—-1797.7%-366.3%-186.4%-1971.6%
Income Tax Expense3K13K10K3K0
Net Income(73M)(70.75M)(54.23M)(50.92M)(70.45M)
Net Margin—-1798.0%-366.4%-186.4%-1971.6%
EPS (Basic)(0.97)(0.85)(0.64)(0.51)(0.70)
EPS (Diluted)(0.97)(0.85)(0.64)(0.51)(0.70)
Weighted Avg Shares74.95M83.55M84.69M99.69M100.75M
Weighted Avg Shares (Diluted)74.95M83.55M84.69M99.69M100.75M

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.